Abstract
Immunoglobulin E (IgE; see ref. 1) has a central role in allergic reactions although it rarely exceeds 5 µg ml−1 even in the serum of severely allergic individuals. Both mast cells and basophils possess receptors which bind the Fc portion of IgE with high affinity; crosslinking of membrane-bound IgE by allergen results in degranulation of the cell and release of a variety of pharmacologically active mediators including histamine. Myeloma IgE has been successfully used to block the skin sensitizing activity of allergic sera2; however, human myeloma IgE is clearly in limited supply. The emergence of techniques allowing the stable introduction of immunoglobulin gene DNA into myeloma cells3–5 has allowed us to construct a mouse cell line that secretes a chimaeric IgE, λ1 antibody whose heavy chain is composed of a human Cε constant region fused to a mouse variable (VH) region. This chimaeric IgE is specific for the hapten 4-hydroxy-3-nitro-phenacetyl (NP) and can, when crosslinked by antigen, trigger the degranulation of human basophils. When not crosslinked, however, the chimaeric IgE can prevent the passive sensitization of these cells by sera from allergic subjects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Möller, G. (ed.) Immun. Rev. 41 (1978).
Stanworth, D. R., Humphrey, J. H., Bennich, H. & Johansson, S. G. O. Lancet ii, 330–332 (1967).
Oi, V. T., Morrison, S. L., Herzenberg, L. A. & Berg, P. Proc. natn. Acad. Sci. U.S.A. 80, 825–829 (1983).
Neuberger, M. S. EMBO J. 2, 1373–1378 (1983).
Ochi, T. et al. Proc. natn. Acad. Sci. U.S.A. 80, 6351–6355 (1983).
Mulligan, R. C. & Berg, P. Proc. natn. Acad. Sci. U.S.A. 78, 2072–2076 (1983).
Banerji, J., Olson, L. A. & Schaffner, W. Cell 33, 729–740 (1983).
Gillies, S. D., Morrison, S. L., Oi, V. T. & Tonegawa, S. Cell 33, 717–728 (1983).
Neuberger, M. S., Williams, G. T. & Fox, R. O. Nature 312, 604–608 (1984).
Johansson, S. G. O. & Bennich, H. Immunology 13, 381 (1967).
Lichtenstein, L. M. & Osler, A. G. J. exp. Med. 120, 507–530 (1964).
Ennis, M. Ag. Actions 12, 60–63 (1982).
Chapman, M. D. & Platts-Mills, T. A. E. J. Immun. 125, 587–592 (1980).
Flanagan, J. G. & Rabbitts, T. H. EMBO J. 1, 655–660 (1982).
Morrison, S. L., Johnson, M. J., Herzenberg, L. A. & Oi, V. T. Proc. natn. Acad. Sci. U.S.A. 81, 6851–6855 (1984).
Boulianne, G. L., Hozumi, N. & Shulman, M. J. Nature 312, 643–646 (1984).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Neuberger, M., Williams, G., Mitchell, E. et al. A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314, 268–270 (1985). https://doi.org/10.1038/314268a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/314268a0
This article is cited by
-
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
Nature Communications (2023)
-
A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth
Scientific Reports (2016)
-
Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction
BMC Biotechnology (2015)
-
Progress in RANK ligand biology: bone and beyond
IBMS BoneKEy (2012)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.